...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Pharmacy and Pharmacology >Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers
【24h】

Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers

机译：使用基于溶液的加压计量吸入器共沉积用于治疗慢性阻塞性肺疾病的三联疗法药物制剂

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives The formulation of multi-drug pressurised metered dose inhalers (pMDIs) opens up exciting therapeutic opportunities for the treatment of asthma and chronic obstructive pulmonary disease (COPD). We have investigated the formulation of a solution-based triple therapy pMDI containing ipratropium, formoterol, budesonide and ethanol as co-solvent. Methods This system was characterised for in-vitro performance and compared with marketed pMDIs (Atrovent and Symbicort). Key findings No significant difference was found in the stage deposition of each drug from the triple therapy formulation, suggesting that the droplets contained a fixed ratio of the three components used. Stage deposition of formoterol and budesonide from the suspension-based marketed Symbicort were significantly different, suggesting that the two drugs were deposited as separate entities. Calculation of the mass median aerodynamic diameter (MMAD) of each formulation suggested Atrovent (ipratropium, MMAD = 0.9 ± 0.0 μm) to have a small particle size, similar to the triple therapy formulation. Atrovent, like the triple therapy formulation was solution based and it contained ethanol as a co-solvent (triple therapy formulation, MMAD = 1.3 ± 0.0 μm). Conclusions This study demonstrated the feasibility of formulating a solution-based pMDI containing a triple therapy with identical deposition pattern for the treatment of several respiratory diseases where multi-drug cell targeting is required.
机译：目的多药加压计量吸入器（pMDIs）的配方为哮喘和慢性阻塞性肺疾病（COPD）的治疗提供了令人兴奋的治疗机会。我们研究了基于溶液的三联疗法pMDI的配方，该溶液含有异丙托铵，福莫特罗，布地奈德和乙醇作为助溶剂。方法对该系统的体外性能进行了表征，并与市售的pMDI（Atrovent和Symbicort）进行了比较。主要发现在三联疗法配方的每种药物的阶段沉积中均未发现明显差异，这表明液滴中所含三种成分的比例固定。福莫特罗和布地奈德在以悬浮液为基础的市场上出售的Symbicort的阶段沉积有显着差异，表明这两种药物是作为独立实体沉积的。每种配方的质量平均空气动力学直径（MMAD）的计算表明，Atrovent（异丙托铵，MMAD = 0.9±0.0μm）具有较小的粒径，类似于三联疗法配方。像三重疗法配方一样，Atrovent是基于溶液的，它含有乙醇作为助溶剂（三重疗法配方，MMAD = 1.3±0.0μm）。结论这项研究证明了配制基于溶液的pMDI的可行性，该溶液包含三重疗法，具有相同的沉积模式，可用于治疗多种需要靶向多种药物的呼吸系统疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号